Women Lose More Weight on Ozempic Than Men. Biology Probably Explains It.
A review of nearly 20,000 people on GLP-1 drugs found that women lost significantly more weight than men. The most meaningful differentiator was not age. It was not race. It was sex.
GLP-1 medications, which include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), work by mimicking hormones that regulate appetite and blood sugar. They have reshaped obesity treatment in the last several years and generated enormous commercial and clinical interest. What has received far less attention is whether they work differently across biological sex, and the answer, it turns out, is yes.
No spam. Unsubscribe anytime.
Researchers suspect the gap is hormonal. Women have different baseline levels of GLP-1 receptors and different estrogen-related signaling pathways that may amplify the drug’s effect on appetite suppression. The mechanism is not yet fully understood, and the researchers say more sex-stratified data is needed before clinical protocols are adjusted.
That caveat matters. The review pooled data from clinical trials and real-world studies, which means the populations were not identical and the results should not be read as a controlled experiment with a clean comparison. What the data does show, consistently, is a directional signal: across studies, women tend to lose more.
The broader context is worth stating plainly. Most of the foundational obesity research, including the trials that led to GLP-1 drug approvals, enrolled predominantly male participants or did not analyze results by sex. The drugs were approved based on average outcomes. “Average” erased the signal that was sitting in the data.
Women make up the majority of GLP-1 users, particularly between ages 30 and 64. A survey from RAND found women are more than twice as likely as men to have used a GLP-1 in the 30-to-49 age group. The drugs were designed without much attention to how they worked in the population most likely to take them.
Researchers are now calling for sex-specific dosing studies. The drugs are expensive, the side effects are real, and the difference in outcomes is large enough to matter clinically. Whether the field moves quickly enough to answer the question is a different kind of test.
Source: MedPage Today, March 2026. Review of nearly 20,000 participants across multiple GLP-1 drug trials and studies.